Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prevalence of SARS-CoV-2 antibodies after the Omicron surge, Kingston, Jamaica, 2022

Journal of Clinical Virology Plus(2022)10.1016/j.jcvp.2022.100124Source: DataRank Database

Prevalence of SARS-CoV-2 antibodies after the Omicron surge, Kingston, Jamaica, 2022 is a research paper published in Journal of Clinical Virology Plus (2022). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.48)OA: goldTopics (27)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Suzette M. Cameron-McDermott,Yakima Z.R. Phillips ORCID,Leshawn Mendoza,Mark Anderson ORCID,Gavin Cloherty

Live enrichment

PubMed:36415687 PMC:PMC9671617 OpenAlex:https://openalex.org/W4309296562

Clinical and Translational Science Institute, Boston University

Grant: D43TW010919

Clinical and Translational Science Institute, Boston University

Grant: UL1TR001412

National Institutes of Health

Grant: 2D43TW010919-06

Global Infectious Diseases Research Training Program

National Institutes of Health

Grant: 3UL1TR001412-08S3

Buffalo Clinical and Translational Research Center

Abbott Laboratories

National Institutes of Health

FWCI

0.48

Citation Percentile

0.6%

Citation Trend

2023

2025

2026

goldLicense: cc-by

journalhttps://www.sciencedirect.com/science/article/pii/S2667038022000631/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2667038022000631/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2667038022000631?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2667038022000631?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcvp.2022.100124

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

SerologyMedicineVaccinationPopulationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyVirologyCoronavirus disease 2019 (COVID-19)ImmunologyEnvironmental healthInternal medicineDiseaseInfectious disease (medical specialty)CaribbeanJamaicaCovid-19Sars-cov-2Spike RbdInfectious and parasitic diseasesRC109-216Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being